organization · Reporting owner

UBS Oncology Impact Fund L.P.

Disclosed activity across 8 companies

Tapewire entity: 72215
SEC CIK: 0001691428

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cullinan Therapeutics, Inc.CGEM · Entity 4766	10% owner	September 16, 2021	September 20, 2021
F-star Therapeutics, Inc.SBPH · Entity 115726	10% owner	March 25, 2017	February 06, 2018
Harpoon Therapeutics, Inc.HARP · Entity 11424	10% owner	May 28, 2021	June 02, 2021
Oncorus, Inc.ONCR · Entity 112213	10% owner	October 06, 2020	October 08, 2020
Viracta Therapeutics, Inc.SNSS · Entity 85616	10% owner	November 02, 2017	November 06, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cullinan Therapeutics, Inc.

Report date September 16, 2021 · Filed September 20, 2021

Jointly reported with Oncology Impact Fund (Cayman) Management L.P., MPM BIOIMPACT LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,648,268	Reported balance After 2021-09-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-09-16 · Sale · Disposed 3,124 · Balance 7,648,268 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.

F4: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

F-star Therapeutics, Inc.

Report date March 25, 2017 · Filed February 06, 2018

Jointly reported with MPM Oncology Impact Management GP LLC, MPM BIOIMPACT LLC, Oncology Impact Fund (Cayman) Management L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	833,839	Reported balance Holding disclosure · report date 2017-03-25 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 833,839 F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology. Ansbert Gadicke is the sole member of MPM GP. However, all voting and investment decisions are made by an investment committee comprised of three or more members, including Ansbert Gadicke. Each member of the investment committee expressly disclaims beneficial ownership of the reported securities.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.79 · Expires 2021-11-23	IndirectSee footnote	Not disclosed	Reported balance Holding disclosure · report date 2017-03-25 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: The warrant was issued on November 23, 2016 but did not become exercisable until May 24, 2017. F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology. Ansbert Gadicke is the sole member of MPM GP. However, all voting and investment decisions are made by an investment committee comprised of three or more members, including Ansbert Gadicke. Each member of the investment committee expressly disclaims beneficial ownership of the reported securities.

Filing footnotes · ownership attribution and instrument terms

F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology. Ansbert Gadicke is the sole member of MPM GP. However, all voting and investment decisions are made by an investment committee comprised of three or more members, including Ansbert Gadicke. Each member of the investment committee expressly disclaims beneficial ownership of the reported securities.

F2: The warrant was issued on November 23, 2016 but did not become exercisable until May 24, 2017.

Harpoon Therapeutics, Inc.

Report date May 28, 2021 · Filed June 02, 2021

Jointly reported with GADICKE ANSBERT, Oncology Impact Fund (Cayman) Management L.P., MPM BIOIMPACT LLC, MPM Oncology Impact Management GP LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,374,904	Reported balance After 2021-05-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-05-28 · Sale · Disposed 10,685 · Balance 6,374,904 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,371,804	Reported balance After 2021-05-28 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-05-28 · Sale · Disposed 3,100 · Balance 6,371,804 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,371,704	Reported balance After 2021-05-28 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-05-28 · Sale · Disposed 100 · Balance 6,371,704 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC. F9: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,353,213	Reported balance After 2021-06-01 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2021-06-01 · Sale · Disposed 18,491 · Balance 6,353,213 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F10: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,328,095	Reported balance After 2021-06-02 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2021-06-02 · Sale · Disposed 25,118 · Balance 6,328,095 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F13: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F15: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.

F2: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F5: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F8: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC.

F9: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F10: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F13: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC.

F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F15: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Oncorus, Inc.

Report date October 06, 2020 · Filed October 08, 2020

Jointly reported with Oncology Impact Fund (Cayman) Management L.P., MPM Oncology Impact Management GP LLC, MPM BIOIMPACT LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,377,025	Last balance in matching sequence After 2020-10-06 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2020-10-06 · Conversion · Acquired 1,525,348 · Balance 1,525,348 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. F3: The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Row 2 · 2020-10-06 · Conversion · Acquired 700,453 · Balance 2,225,801 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. F3: The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Row 3 · 2020-10-06 · Purchase · Acquired 151,224 · Balance 2,377,025 F2: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. F3: The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-06 · Conversion · Disposed 1,525,348 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. F3: The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-10-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-06 · Conversion · Disposed 700,453 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC. F3: The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F2: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.

F3: The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Viracta Therapeutics, Inc.

Report date November 02, 2017 · Filed November 06, 2017

Jointly reported with MPM Oncology Impact Management GP LLC, MPM BIOIMPACT LLC, Oncology Impact Fund (Cayman) Management L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,331,500	Last balance in matching sequence After 2017-11-06 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2017-11-02 · Purchase · Acquired 25,300 · Balance 3,275,300 F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology. Row 2 · 2017-11-03 · Purchase · Acquired 40,000 · Balance 3,315,300 F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology. Row 3 · 2017-11-06 · Purchase · Acquired 16,200 · Balance 3,331,500 F1: MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology.

Filing footnotes · ownership attribution and instrument terms

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

TCR2 THERAPEUTICS INC.

Report date June 01, 2023 · Filed June 05, 2023

Jointly reported with Oncology Impact Fund (Cayman) Management L.P., MPM BIOIMPACT LLC

Section 16 reporting ended · disclosed 2023-06-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2023-06-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-06-01 · Other · Disposed 3,370,982 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F3: The reported securities were held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. F4: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").

F3: The reported securities were held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact.

F4: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

Werewolf Therapeutics, Inc.

Report date December 02, 2025 · Filed December 04, 2025

Jointly reported with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, Oncology Impact Fund (Cayman) Management L.P., MPM BIOIMPACT LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC

Section 16 reporting ended · disclosed 2025-12-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,924,566	Reported balance After 2025-12-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-12-02 · Sale · Disposed 59,277 · Balance 4,924,566 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,867,341	Reported balance After 2025-12-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-12-03 · Sale · Disposed 57,225 · Balance 4,867,341 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,784,111	Reported balance After 2025-12-04 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-12-04 · Sale · Disposed 83,230 · Balance 4,784,111 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F2: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F5: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology.

F6: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology.

F9: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F11: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology.

iTeos Therapeutics, Inc.

Report date May 13, 2025 · Filed May 15, 2025

Jointly reported with GADICKE ANSBERT, MPM BIOIMPACT LLC, Oncology Impact Fund (Cayman) Management L.P.

Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,452,797	Reported balance After 2025-05-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-05-13 · Sale · Disposed 1,031,931 · Balance 3,452,797 F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F2: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.

F2: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 04, 2025 Filed Dec 4, 2025 23:18 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	83,230	$0.97	$80,733.10	Disclosure SEC source: 0001231919-25-000574 · form4-12042025_111237.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Former 10% Owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · Former 10% Owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · Former 10% Owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · Former 10% Owner MPM BioImpact LLC · CIK 0001687078 · Former 10% Owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · Former 10% Owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,784,111 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology. Read SEC document
December 03, 2025 Filed Dec 4, 2025 23:18 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	57,225	$0.87	$49,785.75	Disclosure SEC source: 0001231919-25-000574 · form4-12042025_111237.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Former 10% Owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · Former 10% Owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · Former 10% Owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · Former 10% Owner MPM BioImpact LLC · CIK 0001687078 · Former 10% Owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · Former 10% Owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,867,341 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology. Read SEC document
December 02, 2025 Filed Dec 4, 2025 23:18 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	59,277	$0.89	$52,756.53	Disclosure SEC source: 0001231919-25-000574 · form4-12042025_111237.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Former 10% Owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · Former 10% Owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · Former 10% Owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · Former 10% Owner MPM BioImpact LLC · CIK 0001687078 · Former 10% Owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · Former 10% Owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,924,566 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology. Read SEC document
December 01, 2025 Filed Dec 1, 2025 23:11 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	60,917	$0.94	$57,261.98	Disclosure SEC source: 0001231919-25-000564 · form4-12012025_111253.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,983,843 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014, 5,819 by MPM OIF and 21,821 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014, 473,944 by MPM OIF and 1,787,380 by UBS Oncology. Read SEC document
November 28, 2025 Filed Dec 1, 2025 23:11 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	20,277	$0.99	$20,074.23	Disclosure SEC source: 0001231919-25-000564 · form4-12012025_111253.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,044,760 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014, 1,937 by MPM OIF and 7,263 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014, 479,763 by MPM OIF and 1,809,201 by UBS Oncology. Read SEC document
November 26, 2025 Filed Dec 1, 2025 23:11 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	60,733	$0.98	$59,518.34	Disclosure SEC source: 0001231919-25-000564 · form4-12012025_111253.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,065,037 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,170 by MPM Asset Management LLC ("AM LLC"), 26,343 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,757 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 907 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,801 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,755 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014, 481,700 by MPM OIF and 1,816,464 by UBS Oncology. Read SEC document
November 25, 2025 Filed Nov 25, 2025 23:03 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	42,533	$0.92	$39,130.36	Disclosure SEC source: 0001231919-25-000550 · form4-11252025_111145.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,125,770 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014, 4,063 by MPM OIF and 15,236 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014, 487,501 by MPM OIF and 1,838,219 by UBS Oncology. Read SEC document
November 24, 2025 Filed Nov 25, 2025 23:03 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	88,802	$0.98	$87,025.96	Disclosure SEC source: 0001231919-25-000550 · form4-11252025_111145.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,168,303 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 6,097 by AM LLC, 38,518 by BV 2014, 2,569 by BV 2014(B), 1,325 by AM BV2014, 8,483 by MPM OIF and 31,810 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8733 to $1.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 354,965 by AM LLC, 2,241,648 by BV 2014, 149,514 by BV 2014(B), 77,157 by AM BV2014, 491,564 by MPM OIF and 1,853,455 by UBS Oncology. Read SEC document
November 21, 2025 Filed Nov 25, 2025 23:03 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	64,331	$0.83	$53,394.73	Disclosure SEC source: 0001231919-25-000550 · form4-11252025_111145.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,257,105 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,417 by MPM Asset Management LLC ("AM LLC"), 27,904 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,861 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 960 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,145 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 23,044 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.8861 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 361,062 by AM LLC, 2,280,166 by BV 2014, 152,083 by BV 2014(B), 78,482 by AM BV2014, 500,047 by MPM OIF and 1,885,265 by UBS Oncology. Read SEC document
November 20, 2025 Filed Nov 20, 2025 22:50 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	41,152	$0.89	$36,625.28	Disclosure SEC source: 0001231919-25-000533 · form4-11202025_101121.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,321,436 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 2,825 by AM LLC, 17,850 by BV 2014, 1,191 by BV 2014(B), 614 by AM BV2014, 3,931 by MPM OIF and 14,741 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8506 to $0.9556 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 365,479 by AM LLC, 2,308,070 by BV 2014, 153,944 by BV 2014(B), 79,442 by AM BV2014, 506,192 by MPM OIF and 1,908,309 by UBS Oncology. Read SEC document
November 19, 2025 Filed Nov 20, 2025 22:50 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	66,324	$0.94	$62,344.56	Disclosure SEC source: 0001231919-25-000533 · form4-11202025_101121.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,362,588 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 4,554 by AM LLC, 28,768 by BV 2014, 1,919 by BV 2014(B), 990 by AM BV2014, 6,335 by MPM OIF and 23,758 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.901 to $0.9806 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 368,304 by AM LLC, 2,325,920 by BV 2014, 155,135 by BV 2014(B), 80,056 by AM BV2014, 510,123 by MPM OIF and 1,923,050 by UBS Oncology. Read SEC document
November 18, 2025 Filed Nov 20, 2025 22:50 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	52,627	$0.93	$48,943.11	Disclosure SEC source: 0001231919-25-000533 · form4-11202025_101121.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,428,912 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 3,613 by MPM Asset Management LLC ("AM LLC"), 22,827 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,523 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 786 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,027 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 18,851 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8902 to $0.9601 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 372,858 by AM LLC, 2,354,688 by BV 2014, 157,054 by BV 2014(B), 81,046 by AM BV2014, 516,458 by MPM OIF and 1,946,808 by UBS Oncology. Read SEC document
November 17, 2025 Filed Nov 18, 2025 00:20 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	57,061	$0.95	$54,207.95	Disclosure SEC source: 0001231919-25-000507 · form4-11182025_121121.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,481,539 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 3,918 by AM LLC, 24,750 by BV 2014, 1,651 by BV 2014(B), 851 by AM BV2014, 5,451 by MPM OIF and 20,440 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9183 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 376,471 by AM LLC, 2,377,515 by BV 2014, 158,577 by BV 2014(B), 81,832 by AM BV2014, 521,485 by MPM OIF and 1,965,659 by UBS Oncology. Read SEC document
November 14, 2025 Filed Nov 18, 2025 00:20 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	61,640	$0.93	$57,325.20	Disclosure SEC source: 0001231919-25-000507 · form4-11182025_121121.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,538,600 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 4,232 by AM LLC, 26,736 by BV 2014, 1,783 by BV 2014(B), 921 by AM BV2014, 5,888 by MPM OIF and 22,080 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.895 to $0.9551 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 380,389 by AM LLC, 2,402,265 by BV 2014, 160,228 by BV 2014(B), 82,683 by AM BV2014, 526,936 by MPM OIF and 1,986,099 by UBS Oncology. Read SEC document
November 13, 2025 Filed Nov 18, 2025 00:20 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	90,951	$0.98	$89,131.98	Disclosure SEC source: 0001231919-25-000507 · form4-11182025_121121.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,600,240 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 6,244 by MPM Asset Management LLC ("AM LLC"), 39,450 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,631 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,359 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,688 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 32,579 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.918 to $1.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 384,621 by AM LLC, 2,429,001 by BV 2014, 162,011 by BV 2014(B), 83,604 by AM BV2014, 532,824 by MPM OIF and 2,008,179 by UBS Oncology. Read SEC document
November 12, 2025 Filed Nov 13, 2025 00:31 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	40,669	$1.09	$44,329.21	Disclosure SEC source: 0001231919-25-000459 · form4-11132025_121146.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,691,191 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F12 · shares: The shares were sold as follows: 2,792 by AM LLC, 17,640 by BV 2014, 1,177 by BV 2014(B), 607 by AM BV2014, 3,885 by MPM OIF and 14,568 by UBS Oncology. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.065 to $1.145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F14 · ownership.nature: The shares are held as follows: 390,865 by AM LLC, 2,468,451 by BV 2014, 164,642 by BV 2014(B), 84,963 by AM BV2014, 541,512 by MPM OIF and 2,040,758 by UBS Oncology. Read SEC document
November 11, 2025 Filed Nov 13, 2025 00:31 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	55,810	$1.14	$63,623.40	Disclosure SEC source: 0001231919-25-000459 · form4-11132025_121146.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,731,860 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 3,832 by AM LLC, 24,208 by BV 2014, 1,615 by BV 2014(B), 832 by AM BV2014, 5,331 by MPM OIF and 19,992 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.115 to $1.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 393,657 by AM LLC, 2,486,091 by BV 2014, 165,819 by BV 2014(B), 85,570 by AM BV2014, 545,397 by MPM OIF and 2,055,326 by UBS Oncology. Read SEC document
November 10, 2025 Filed Nov 13, 2025 00:31 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	48,570	$1.18	$57,312.60	Disclosure SEC source: 0001231919-25-000459 · form4-11132025_121146.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,787,670 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,335 by AM LLC, 21,067 by BV 2014, 1,405 by BV 2014(B), 725 by AM BV2014, 4,640 by MPM OIF and 17,398 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.145 to $1.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 397,489 by AM LLC, 2,510,299 by BV 2014, 167,434 by BV 2014(B), 86,402 by AM BV2014, 550,728 by MPM OIF and 2,075,318 by UBS Oncology. Read SEC document
November 07, 2025 Filed Nov 13, 2025 00:31 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	68,480	$1.11	$76,012.80	Disclosure SEC source: 0001231919-25-000459 · form4-11132025_121146.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,836,240 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,702 by MPM Asset Management LLC ("AM LLC"), 29,704 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,981 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,022 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,541 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 24,530 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.075 to $1.188 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 400,824 by AM LLC, 2,531,366 by BV 2014, 168,839 by BV 2014(B), 87,127 by AM BV2014, 555,368 by MPM OIF and 2,092,716 by UBS Oncology. Read SEC document
November 06, 2025 Filed Nov 7, 2025 00:40 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	54,452	$1.21	$65,886.92	Disclosure SEC source: 0001231919-25-000439 · form4-11072025_121138.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 5,904,720 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 3,738 by AM LLC, 23,619 by BV 2014, 1,575 by BV 2014(B), 814 by AM BV2014, 5,201 by MPM OIF and 19,505 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.185 to $1.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 405,526 by AM LLC, 2,561,070 by BV 2014, 170,820 by BV 2014(B), 88,149 by AM BV2014, 561,909 by MPM OIF and 2,117,246 by UBS Oncology. Read SEC document
November 05, 2025 Filed Nov 7, 2025 00:40 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	47,950	$1.22	$58,499.00	Disclosure SEC source: 0001231919-25-000439 · form4-11072025_121138.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 5,959,172 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,292 by AM LLC, 20,798 by BV 2014, 1,387 by BV 2014(B), 717 by AM BV2014, 4,580 by MPM OIF and 17,176 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 409,264 by AM LLC, 2,584,689 by BV 2014, 172,395 by BV 2014(B), 88,963 by AM BV2014, 567,110 by MPM OIF and 2,136,751 by UBS Oncology. Read SEC document
November 04, 2025 Filed Nov 7, 2025 00:40 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	140,488	$1.22	$171,395.36	Disclosure SEC source: 0001231919-25-000439 · form4-11072025_121138.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,007,122 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 9,645 by MPM Asset Management LLC ("AM LLC"), 60,937 by MPM BioVentures 2014, L.P. ("BV 2014"), 4,064 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 2,098 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,420 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 50,324 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F3 · shares: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 412,556 by AM LLC, 2,605,487 by BV 2014, 173,782 by BV 2014(B), 89,680 by AM BV2014, 571,690 by MPM OIF and 2,153,927 by UBS Oncology. Read SEC document
November 03, 2025 Filed Nov 4, 2025 00:07 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	94,063	$1.29	$121,341.27	Disclosure SEC source: 0001231919-25-000404 · form4-11042025_121157.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,147,610 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 6,458 by AM LLC, 40,800 by BV 2014, 2,721 by BV 2014(B), 1,405 by AM BV2014, 8,985 by MPM OIF and 33,694 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.245 to $1.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 422,201 by AM LLC, 2,666,424 by BV 2014, 177,846 by BV 2014(B), 91,778 by AM BV2014, 585,110 by MPM OIF and 2,204,251 by UBS Oncology. Read SEC document
October 31, 2025 Filed Nov 4, 2025 00:07 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	114,044	$1.28	$145,976.32	Disclosure SEC source: 0001231919-25-000404 · form4-11042025_121157.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,241,673 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 7,830 by AM LLC, 49,467 by BV 2014, 3,299 by BV 2014(B), 1,702 by AM BV2014, 10,894 by MPM OIF and 40,852 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.205 to $1.415 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 428,659 by AM LLC, 2,707,224 by BV 2014, 180,567 by BV 2014(B), 93,183 by AM BV2014, 594,095 by MPM OIF and 2,237,945 by UBS Oncology. Read SEC document
October 30, 2025 Filed Nov 4, 2025 00:07 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	86,936	$1.43	$124,318.48	Disclosure SEC source: 0001231919-25-000404 · form4-11042025_121157.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,355,717 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 5,969 by MPM Asset Management LLC ("AM LLC"), 37,709 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,515 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,298 MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,304 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 31,141 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F3 · shares: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.365 to $1.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 436,489 by AM LLC, 2,756,691 by BV 2014, 183,866 by BV 2014(B), 94,885 by AM BV2014, 604,989 by MPM OIF and 2,278,797 by UBS Oncology. Read SEC document
October 29, 2025 Filed Oct 29, 2025 23:21 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	134,240	$1.55	$208,072.00	Disclosure SEC source: 0001231919-25-000373 · form4-10292025_111002.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,442,653 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 9,216 by AM LLC, 58,227 by BV 2014, 3,884 by BV 2014(B), 2,004 by AM BV2014, 12,823 by MPM OIF and 48,086 by UBS Oncology F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 442,458 by AM LLC, 2,794,400 by BV 2014, 186,381 by BV 2014(B), 96,183 by AM BV2014, 613,293 by MPM OIF and 2,309,938 by UBS Oncology. Read SEC document
October 28, 2025 Filed Oct 29, 2025 23:21 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	69,068	$1.64	$113,271.52	Disclosure SEC source: 0001231919-25-000373 · form4-10292025_111002.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,576,893 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 4,742 by AM LLC, 29,958 by BV 2014, 1,998 by BV 2014(B), 1,031 by AM BV2014, 6,598 by MPM OIF and 24,741 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.605 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 451,674 by AM LLC, 2,852,627 by BV 2014, 190,265 by BV 2014(B), 98,187 by AM BV2014, 626,116 by MPM OIF and 2,358,024 by UBS Oncology. Read SEC document
October 27, 2025 Filed Oct 29, 2025 23:21 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	72,709	$1.72	$125,059.48	Disclosure SEC source: 0001231919-25-000373 · form4-10292025_111002.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,645,961 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,992 by MPM Asset Management LLC ("AM LLC"), 31,538 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,104 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,085 MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,945 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 26,045 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F3 · shares: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.675 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 456,416 by AM LLC, 2,882,585 by BV 2014, 192,263 by BV 2014(B), 99,218 by AM BV2014, 632,714 by MPM OIF and 2,382,765 by UBS Oncology. Read SEC document
May 13, 2025 Filed May 15, 2025 21:34 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	1,031,931	$8.06	$8,317,363.86	Disclosure SEC source: 0001415889-25-013252 · form4-05152025_090510.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Former 10% Owner MPM BioImpact LLC · CIK 0001687078 · Former 10% Owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · Former 10% Owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,452,797 F1 · shares: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F2 · shares: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
March 27, 2025 Filed Apr 30, 2025 20:08 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	OtherWarrant (Right to Buy) · Derivative	42,842	$0.00 Strike: $0.09	$0.00	Disclosure SEC source: 0001415889-25-011569 · form4-04302025_080446.xml · derivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 42,842 shares Expires 2025-08-13 F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares. F5 · derivative.exercise_date: Immediately exercisable. F7 · ownership.nature: The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV 2014, 5,355 by MPM OIF and 18,744 by UBS Oncology. Read SEC document
March 27, 2025 Filed Apr 30, 2025 20:08 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	OtherWarrant (Right to Buy) · Derivative	8,031	$0.00 Strike: $0.09	$0.00	Disclosure SEC source: 0001415889-25-011569 · form4-04302025_080446.xml · derivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 8,031 shares Expires 2025-04-09 F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares. F5 · derivative.exercise_date: Immediately exercisable. F6 · ownership.nature: The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B), 125 by AM BV 2014 and 4,016 by UBS Oncology. Read SEC document
March 27, 2025 Filed Apr 30, 2025 20:08 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	4,386	$1.05	$4,605.30	Disclosure SEC source: 0001415889-25-011569 · form4-04302025_080446.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 6,718,670 F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares. F4 · ownership.nature: The shares are held as follows: 461,408 by AM LLC, 2,914,123 by BV 2014, 194,367 by BV 2014(B), 100,303 by AM BV2014, 639,659 by MPM OIF and 2,408,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document
March 27, 2025 Filed Apr 30, 2025 20:08 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	OtherCommon Stock	50,873	$0.09	$4,578.57	Disclosure SEC source: 0001415889-25-011569 · form4-04302025_080446.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 6,723,056 F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares. F2 · ownership.nature: The shares are held as follows: 461,408 by MPM Asset Management LLC ("AM LLC"), 2,915,905 by MPM BioVentures 2014, L.P. ("BV 2014"), 194,486 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 100,365 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 640,121 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 2,410,771 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F3 · ownership.nature: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document
June 01, 2023 Filed Jun 5, 2023 16:37 UTC	TCR2 THERAPEUTICS INC. TCRR · Entity 94327	OtherCommon Stock	3,370,982	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034346 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F3 · ownership.direct: The reported securities were held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. F4 · ownership.direct: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document
January 05, 2022 Filed Jan 6, 2022 21:12 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	30,347	$42.03	$1,275,484.41	Disclosure SEC source: 0001209191-22-002167 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,484,728 F14 · shares: The shares were sold as follows: 10,804 by BV 2014, 372 by AM BV2014, 6,824 by BV 2018, 135 by AM BV2018 and 12,212 by UBS Oncology. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F16 · ownership.nature: The shares are held as follows: 1,544,580 by BV 2014, 97,289 by, 53,164 by AM BV2014, 975,523 by BV 2018, 48,966 by BV 2018(B), 19,263 by AM BV2018 and 1,745,943 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
January 04, 2022 Filed Jan 6, 2022 21:12 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	12,829	$46.47	$596,163.63	Disclosure SEC source: 0001209191-22-002167 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,515,075 F11 · shares: The shares were sold as follows: 4,590 by BV 2014, 154 by AM BV2014, 2,874 by BV 2018, 53 by AM BV2018 and 5,158 by UBS Oncology. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.025 to $46.965 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 1,555,384 by BV 2014, 97,289 by BV 2014(B), 53,536 by AM BV2014, 982,347 by BV 2018, 48,966 by BV 2018(B), 19,398 by AM BV2018 and 1,758,155 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
January 04, 2022 Filed Jan 6, 2022 21:12 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	11,318	$45.32	$512,931.76	Disclosure SEC source: 0001209191-22-002167 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,527,904 F8 · shares: The shares were sold as follows: 4,050 by BV 2014, 133 by AM BV2014, 2,544 by BV 2018, 41 by AM BV2018 and 4,550 by UBS Oncology. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 1,559,974 by BV 2014, 97,289 by BV 2014(B), 53,690 by AM BV2014, 985,221 by BV 2018, 48,966 by BV 2018(B), 19,451 by AM BV2018 and 1,763,313 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
January 04, 2022 Filed Jan 6, 2022 21:12 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	32,396	$43.20	$1,399,507.20	Disclosure SEC source: 0001209191-22-002167 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,539,222 F5 · shares: The shares were sold as follows: 11,534 by BV 2014, 390 by AM BV2014, 7,300 by BV 2018, 142 by AM BV2018 and 13,030 by UBS Oncology. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 1,564,024 by BV 2014, 97,289 by BV 2014(B), 53,823 by AM BV2014, 987,765 by BV 2018, 48,966 by BV 2018(B), 19,492 by AM BV2018 and 1,767,863 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
January 04, 2022 Filed Jan 6, 2022 21:12 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	158,579	$42.05	$6,668,246.95	Disclosure SEC source: 0001209191-22-002167 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,571,618 F1 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F2 · shares: The shares were sold as follows: 56,414 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,959 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 35,653 by MPM BioVentures 2018, L.P. ("BV 2018"), 719 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 63,834 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 1,575,558 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 54,213 by AM BV2014, 995,065 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 19,634 by AM BV2018 and 1,780,893 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
December 07, 2021 Filed Dec 7, 2021 23:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	2,499	$34.11	$85,240.89	Disclosure SEC source: 0001209191-21-068406 · doc4.xml · nonDerivative · entry 9 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,730,197 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F25 · shares: The shares were sold as follows: 890 by BV 2014, 31 by AM BV2014, 562 by BV 2018, 11 by AM BV2018 and 1,005 by UBS Oncology. F26 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.875 to $34.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F27 · ownership.nature: The shares are held as follows: 1,631,972 by BV 2014, 97,289 by BV 2014(B), 56,172 by AM BV2014, 1,030,718 by BV 2018, 48,966 by BV 2018(B), 20,353 by AM BV2018 and 1,844,727 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
December 07, 2021 Filed Dec 7, 2021 23:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	30,059	$33.15	$996,455.85	Disclosure SEC source: 0001209191-21-068406 · doc4.xml · nonDerivative · entry 8 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,732,696 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F22 · shares: The shares were sold as follows: 10,701 by BV 2014, 368 by AM BV2014, 6,759 by BV 2018, 134 by AM BV2018 and 12,097 by UBS Oncology. F23 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.84 to $33.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F24 · ownership.nature: The shares are held as follows: 1,632,862 by BV 2014, 97,289 by BV 2014(B), 56,203 by AM BV2014, 1,031,280 by BV 2018, 48,966 by BV 2018(B), 20,364 by AM BV2018 and 1,845,732 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
December 06, 2021 Filed Dec 7, 2021 23:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	100	$35.04	$3,504.00	Disclosure SEC source: 0001209191-21-068406 · doc4.xml · nonDerivative · entry 7 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,762,755 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F20 · shares: The shares were sold as follows: 35 by BV 2014, 2 by AM BV2014, 22 by BV 2018, 1 by AM BV2018 and 40 by UBS Oncology. F21 · ownership.nature: The shares are held as follows: 1,643,563 by BV 2014, 97,289 by BV 2014(B), 56,571 by AM BV2014, 1,038,039 by BV 2018, 48,966 by BV 2018(B), 20,498 by AM BV2018 and 1,857,829 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
December 06, 2021 Filed Dec 7, 2021 23:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	850	$34.08	$28,968.00	Disclosure SEC source: 0001209191-21-068406 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,762,855 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F17 · shares: The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014, 191 by BV 2018, 4 by AM BV2018 and 342 by UBS Oncology. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.125 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F19 · ownership.nature: The shares are held as follows: 1,643,598 by BV 2014, 97,289 by BV 2014(B), 56,573 by AM BV2014, 1,038,061 by BV 2018, 48,966 by BV 2018(B), 20,499 by AM BV2018 and 1,857,869 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
December 06, 2021 Filed Dec 7, 2021 23:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	1,960	$33.57	$65,797.20	Disclosure SEC source: 0001209191-21-068406 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,763,705 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F14 · shares: The shares were sold as follows: 698 by BV 2014, 24 by AM BV2014, 441 by BV 2018, 8 by AM BV2018 and 789 by UBS Oncology. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.99 to $33.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F16 · ownership.nature: The shares are held as follows: 1,643,901 by BV 2014, 97,289 by, 56,583 by AM BV2014, 1,038,252 by BV 2018, 48,966 by BV 2018(B), 20,503 by AM BV2018 and 1,858,211 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
December 06, 2021 Filed Dec 7, 2021 23:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	14,173	$32.35	$458,496.55	Disclosure SEC source: 0001209191-21-068406 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,765,665 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F11 · shares: The shares were sold as follows: 5,046 by BV 2014, 173 by AM BV2014, 3,187 by BV 2018, 63 by AM BV2018 and 5,704 by UBS Oncology. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.98 to $32.975 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 1,644,599 by BV 2014, 97,289 by BV 2014(B), 56,607 by AM BV2014, 1,038,693 by BV 2018, 48,966 by BV 2018(B), 20,511 by AM BV2018 and 1,859,000 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
December 03, 2021 Filed Dec 7, 2021 23:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	300	$36.26	$10,878.00	Disclosure SEC source: 0001209191-21-068406 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,779,838 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F9 · shares: The shares were sold as follows: 107 by BV 2014, 4 by AM BV2014, 67 by BV 2018, 1 by AM BV2018 and 121 by UBS Oncology. F10 · ownership.nature: The shares are held as follows: 1,649,645 by BV 2014, 97,289 by BV 2014(B), 56,780 by AM BV2014, 1,041,880 by BV 2018, 48,966 by BV 2018(B), 20,574 by AM BV2018 and 1,864,704 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
December 03, 2021 Filed Dec 7, 2021 23:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	4,047	$35.44	$143,425.68	Disclosure SEC source: 0001209191-21-068406 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,780,138 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 1,441 by BV 2014, 50 by AM BV2014, 910 by BV 2018, 18 by AM BV2018 and 1,628 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.15 to $36.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 1,649,752 by BV 2014, 97,289 by BV 2014(B), 56,784 by AM BV2014, 1,041,947 by BV 2018, 48,966 by BV 2018(B), 20,575 by AM BV2018 and 1,864,825 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
December 03, 2021 Filed Dec 7, 2021 23:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	29,402	$34.68	$1,019,661.36	Disclosure SEC source: 0001209191-21-068406 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,784,185 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F3 · shares: The shares were sold as follows: 10,467 by MPM BioVentures 2014, L.P. ("BV 2014"), 359 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,612 by MPM BioVentures 2018, L.P. ("BV 2018"), 131 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 11,833 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.15 to $35.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 1,651,193 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 56,834 by AM BV2014, 1,042,857 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 20,593 by AM BV2018 and 1,866,453 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
December 02, 2021 Filed Dec 2, 2021 23:53 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	12,434	$34.83	$433,076.22	Disclosure SEC source: 0001209191-21-067705 · doc4.xml · nonDerivative · entry 7 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,813,587 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F21 · shares: The shares were sold as follows: 4,427 by BV 2014, 152 by AM BV2014, 2,796 by BV 2018, 55 by AM BV2018 and 5,004 by UBS Oncology. F22 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F23 · ownership.nature: The shares are held as follows: 1,661,660 by BV 2014, 97,289 by BV 2014(B), 57,193 by AM BV2014, 1,049,469 by BV 2018, 48,966 by BV 2018(B), 20,724 by AM BV2018 and 1,878,286 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
December 02, 2021 Filed Dec 2, 2021 23:53 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	49,796	$33.74	$1,680,117.04	Disclosure SEC source: 0001209191-21-067705 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,826,021 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F18 · shares: The shares were sold as follows: 17,728 by BV 2014, 611 by AM BV2014, 11,197 by BV 2018, 221 by AM BV2018 and 20,039 by UBS Oncology. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.19 to $34.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F20 · ownership.nature: The shares are held as follows: 1,666,087 by BV 2014, 97,289 by BV 2014(B), 57,345 by AM BV2014, 1,052,265 by BV 2018, 48,966 by BV 2018(B), 20,779 by AM BV2018 and 1,883,290 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.